Abstract:
The present invention describes dental adhesive compositions used for bonding dental biomaterials to hard tissue comprising a polymerizable blend of one or more newly synthesized low shrinkage, stable, multifunctional compounds, where the compounds are acidic-methacrylate derivatives, having excellent properties of bonding the hard tooth substance (enamel or dentin) to dental restorative materials, and present high quality marginal sealing between the tooth and the material thus bond and improved storage stability

Description:
FIELD OF THE INVENTION 
       [0001]    The invention relates to multifunctional molecules containing acidic polymerizable monomers, processes for making the monomers and compositions comprising the monomers. The invention relates to primer compositions and to adhesive bonding systems using such compositions. The present invention also comprises methods of using the monomers, such as in dental applications, and in particular, dental total-etching or self-etching adhesives in a single-component or in a multi-component presentation. 
       BACKGROUND OF THE INVENTION 
       [0002]    Dental adhesives have dramatically changed the options available for restoration placements since their introduction more than forty years ago. Initially, the use of dental adhesives required a long etching time and were only recommended for etching and bonding of the enamel. Dental bonding systems have evolved and become more effective with advances in chemistry, application, mechanism, and technique. 
         [0003]    Currently used dental adhesives contain different monomer components in addition to the initiator system and solvent, such as water, ethanol, acetone or mixtures thereof. The requirements for enamel-dentin adhesives include removal of the smear layer on top of the dentin, creation of an adequate etch pattern (demineralization) on the tooth structure in a short period of time, and diffusion of monomers into etched enamel and dentin. 
         [0004]    For the purpose of the present invention, dental adhesives will be classified into two main groups, etch and rinse (“total etch”) and a self-etching type. In the case of total etch adhesives, the surface of the tooth is treated or etched beforehand with a solution of phosphoric acid, and then, while the tooth is still wet from water cleansing, the adhesive is applied with a bonding agent. In the case of self-etching adhesives, the tooth surface is thoroughly dried by application of blowing air and subjected, without any pretreatment, to application of an acidic-bonding agent having a function of an etching agent. A bonding layer can be applied simultaneously to the surface of the tooth. By the use of the self-etching bonding agents, the pretreatment process with phosphoric acid is eliminated. 
         [0005]    Ideally, the dental professional would use the etching, priming and adhesive bonding system in a manner that minimizes the time required for a patient to be in the dental chair. In addition, an ideal etching, priming and adhesive bonding system would also provide consistently high and stable bond strength of adhesives, composites, resins, metals and other dental prostheses to dentin and enamel. In the field of dental adhesives, several materials have been developed having excellent adhesiveness to a tooth, especially to the enamel portion. However, there is a need in the art for dental adhesives that provide further improved adhesion as well as no marginal gap formation when a dental restorative material is applied to a tooth. 
       DESCRIPTION OF THE RELATED ART 
       [0006]    Yeniad et al., “Synthesis and photopolymerization of new phosphonated monomers for dental applications,” Journal of Polymer Science: Part A: Polymer Chemistry, Vol. 46, No 6 (2008): pp. 2290-2299, discloses the synthesis of phosphonate monomers from the reaction of glycidyl methacrylate with (diethoxy-phosphoryl)acetic acid or (2-hydroxy-ethyl)-phosphonic acid dimethyl ester. 
         [0007]    Youssef et al. “New phosphonated methacrylates: Synthesis, photocuring and study of their thermal and flame-retardant properties,” Macromol. Chem. Phys., Vol. 204 (2003), 1842-1850, discloses the synthesis of methacrylate phosphonate monomer according to two different pathways. 
         [0008]    Brunet et al., “Solid-state reshaping on nanostructured crystals: supramolecular chirality of layered materials derived from polyethylenoxa-pillared zirconium phosphate,” Tetrahedron: Asymmetry, vol. 17 (2006): pp. 347-354, discloses the synthesis of diethyl[2-(oxyran-2-ylmethoxy)ethyl]phosphonate from the reaction of diethyl-vinylphosphonate and glycidol in the presence of CsCO 3  and its reaction with hexaethyleneglycol. 
         [0009]    U.S. Patent Application 2009/0043008 A1 discloses a one part self-etching, self-priming dental adhesive with improved storage stability due to use of a specific thermal polymerization inhibitor, self priming dental adhesive having pH of at most 2. 
         [0010]    U.S. Patent Application 2008/0194730A1 discloses an aqueous one-pack self-etching and self-priming dental adhesive composition having a pH of at most 2, which comprises: (i) a polymerizable N-substituted alkylacrylic or acrylic amide monomer with an optional inorganic acidic moiety selected from a phosphonic acid or sulfonic acid, and (ii) a curing system. 
         [0011]    U.S. Pat. No. 4,612,384 shows a polymerizable composition containing phosphate monoester adhesive compositions. 
       SUMMARY OF THE INVENTION 
       [0012]    There is an unmet need for compounds that can be used in dental adhesive compositions that have excellent bonding properties, high quality marginal sealing, and improved storage stability. The present invention addresses the unmet needs in the art and provides novel low shrinkage multifunctional molecules for dental bonding applications, having improved adhesion and which exhibit improved properties of bonding the hard tooth substance (i.e. enamel, dentin) to dental restorative materials. The molecules also form a high quality seal between the tooth and the material bonded thereto and provide improved storage stability. 
         [0013]    The present invention provides for compounds which are acidic-methacylate derivatives, and compositions comprising such compounds. 
         [0014]    The present invention also provides for methods for producing the acidic-methacylate derivatives. 
         [0015]    The present invention also provides for methods of using compositions comprising the acidic-methacrylic derivatives in dental applications. 
       DETAILED DESCRIPTION OF THE INVENTION 
       [0016]    The present invention relates to a compound selected from the group consisting of: 
         [0017]    (I) a compound of formula (I): 
         [0000]    
       
                 
         
             
             
         
       
       
         
           
             wherein the ring structure of formula (I) is preferably saturated or contains up to three unsaturations, and wherein:
           Y 1 -Y 6 , each independent from each other, is selected from the group consisting of: C, O, N, and S, with the proviso that at least three of Y 1 -Y 6  are C, and wherein:   (i) when any one of Y 1 -Y 6  is O, S, or an unsaturated nitrogen then the corresponding H, X 1 -X 6  and Z 1 -Z 6  are absent;   (ii) when any one of Y 1 -Y 6  is a saturated nitrogen or an unsaturated carbon, then the corresponding H is absent;   X 1 -X 6 , each independent from each other, is a direct bond, or is selected from the group consisting of: ═O, ═S, ═N—, and R X , wherein when any one of X 1 -X 6  is ═O or ═S, then the corresponding Z 1 -Z 6  is absent, wherein R X  is a C 1 -C 15  group optionally having at least one unsaturation, branch and/or cycle, which is substituted up to 4 times or unsubstituted, and which may be interrupted by at least one O or S, wherein the substituents are each independently selected from the group consisting of —OH, —OR V , ═O, ═S, —O 2 CR V , —SH, —SR V , —SOCR V , —NH 2 , —NHR V , —N(R V ) 2 , —NHCOR V , —NRCOR V , —I, —Br, —Cl, —F, —CN, —CO 2 H, —CO 2 R V , —CHO, —COR V , —CONH 2 , —CONHR V , —CON(R V ) 2 , —COSH, —COSR V , —NO 2 , —SO 3 H, —SOR V , and —SO 2 R V , wherein R V  is a linear, branched or cyclic alkyl of one to ten carbon atoms,   Z 1 -Z 6 , each independent from each other, is R S , wherein R S  is selected from the group consisting of:
               (a) H;   (b) a radical of formula (IV)   
               
         
           
         
       
     
         [0000]    
       
                 
         
             
             
         
       
       
         
           
             wherein:
           n1 and n2, each independent from each other, is 0 or 1;   n3 and n4, each independent from each other, is 0 to 6;   R 1  to R 12 , each independent from each other, is selected from the group consisting of:
               (i) H,   (ii) R Y , wherein R Y  is C 1 -C 6  group optionally having at least one unsaturation, branch and/or cycle, which is substituted up to 2 times or unsubstituted, and which may be interrupted by at least one O or S, wherein the substituents are each independently selected from the group consisting of —OH, —OR, ═O, ═S, —O 2 OR, —SH, —SR, —SOCR, —NH 2 , —NHR, —N(R) 2 , —NHCOR, —NRCOR, —I, —Br, —Cl, —F, —ON, —CO 2 H, —CO 2 R, —CHO, —COR, —CONH 2 , —CONHR, —CON(R) 2 , —COSH, —COSR, —NO 2 , —SO 3 H, —SOR, and —SO 2 R, wherein R is a linear or branched alkyl of one to three carbon atoms, and   (iii) a radical of formula (V):   
               
         
           
         
       
     
         [0000]    
       
                 
         
             
             
         
       
       
         
           
             wherein:
           R A  is R X , as defined above, and m1 is 0 or 1,   R B  is O or S,   m2 is 0 or 1;   R Z  is selected from the group consisting of:   
         
           
         
       
     
         [0000]    
       
                 
         
             
             
         
       
       
         
           
             
               
                  and a C 1 -C 3  group optionally having at least one unsaturation or branch, which is substituted up to 2 times or unsubstituted, and which may be interrupted by at least one O or S, wherein the substituents are each independently selected from the group consisting of —OH, —OR, ═O, ═S, —O 2 CR, —SH, —SR, —SOCR, —NH 2 , —NHR, —N(R) 2 , —NHCOR, —NRCOR, —I, —Br, —Cl, —F, —CN, —CO 2 H, —CO 2 R, —CHO, —COR, —CONH 2 , —CONHR, —CON(R) 2 , —COSH, —COSR, —NO 2 , —SO 3 H, —SOR, and —SO 2 R, wherein R is a linear or branched alkyl of one to three carbon atoms, 
                 R D  is selected from the group consisting of: 
                 (i) 
               
             
           
         
       
     
         [0000]    
       
                 
         
             
             
         
       
       
         
           
             
               
                  wherein R E  is H or R Y , as defined above; and 
                 (ii) 
               
             
           
         
       
     
         [0000]    
       
                 
         
             
             
         
       
       
         
           
             
               
                  wherein R F  and R G , each independent from each other, are selected from the group consisting of: H and R Y , as defined above; and wherein at least one of R 1  to R 12  is a radical of formula (V); and 
               
             
           
         
       
     
         [0041]    (II) a compound of formula (II): 
         [0000]    
       
                 
         
             
             
         
       
       
         
           
             wherein:
           Z 7  is R S , as defined above,   q1 and q2, each independent from each other, is 0 or 1, and preferably, when q2 is 1, then q1 is 0   R X  is as defined above, and   Z 8  is a radical of formula (IV), as defined above; and   
         
           
         
       
     
         [0047]    (III) a compound of formula (III): 
         [0000]    
       
                 
         
             
             
         
       
       
         
           
             wherein:
           X A , X B , X C , and X D , each independent from each other, is a direct bond or R Y , wherein R Y  is C 1 -C 6  group optionally having at least one unsaturation, branch and/or cycle, which is substituted up to 2 times or unsubstituted, and which may be interrupted by at least one O or S, wherein the substituents are each independently selected from the group consisting of —OH, —OR, ═O, ═S, —O 2 CR, —SH, —SR, —SOCR, —NH 2 , —NHR, —N(R) 2 , —NHCOR, —NRCOR, —I, —Br, —Cl, —F, —CN, —CO 2 H, —CO 2 R, —CHO, —COR, —CONH 2 , —CONHR, —CON(R) 2 , —COSH, —COSR, —NO 2 , —SO 3 H, —SOR, and —SO 2 R, wherein R is a linear or branched alkyl of one to three carbon atoms, and preferably, X A , X B , X C , and X D  are each unsubstituted C 1  alkyl groups;   Y A , Y B , Y C , and Y D , each independent from each other, is H or COOH, with the proviso that at least two of Y A , Y B , Y C , and Y D  are COOH, and preferably Y A , Y B , Y C , and Y D  are each COOH;   L is selected from the group consisting of:   (a) a direct bond,   (b)   
         
           
         
       
     
         [0000]    
       
                 
         
             
             
         
       
       
         
           
             
               
                 and 
                 (c) R Y , as defined above; and 
                 A 1 , A 2 , and A 3 , each independent of each other, are H or R Y  as defined above, and preferably A 1 , A 2 , and A 3  are each H. 
               
             
           
         
       
     
         [0057]    In some preferred embodiments, in formula (I): (1) Y 1 -Y 6  are all C; or (2) one of Y 1 -Y 6  is O, and the remainder of Y 1 -Y 6  are C. In some preferred embodiments, in formula (I), two of X 1 -X 6  are ═O, and one of X 1 -X 6  is ═N—. In some preferred embodiments, in formula (I), at least 3 of X 1 -X 6  are R X , wherein R X  is a C 5 -C 9  alkyl. 
         [0058]    In some preferred embodiments, in formula (IV), R 1 -R 12  are H. In some preferred embodiments, in formula (IV), n3 and n4 are 1. In some preferred embodiments, in formula (IV), n2 is 1. In some preferred embodiments, in formula (IV), R 1  is H, n1 is 1, and n2 is 1. In some preferred embodiments, in formula (IV), R 4  or R 6  is a radical of formula (V). 
         [0059]    In some preferred embodiments, in formula (V), R D  is 
         [0000]    
       
                 
         
             
             
         
       
     
         [0060]    In some preferred embodiments, R Z  is a C 1 -C 2  alkyl or 
         [0000]    
       
                 
         
             
             
         
       
     
         [0061]    In some preferred embodiments, in formula (V), m2 is 1 and R B  is O. In some preferred embodiments, in formula (V), R A  is a C 1  alkyl and m1 is 1. 
         [0062]    In some preferred embodiments, in formula (III), L is a direct bond or is selected from the group consisting of: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0000]    The present invention also relates to the compound of formula (1): 
         [0000]    
       
                 
         
             
             
         
       
     
         [0063]    The present invention also relates to the compound of formula (2): 
         [0000]    
       
                 
         
             
             
         
       
     
         [0064]    The present invention also relates to the compound of formula (3): 
         [0000]    
       
                 
         
             
             
         
       
     
         [0065]    The present invention also relates to the compound of formula (4): 
         [0000]    
       
                 
         
             
             
         
       
     
         [0066]    The present invention also relates to the compound of formula (5): 
         [0000]    
       
                 
         
             
             
         
       
     
         [0067]    The present invention also relates to the compound of formula (6): 
         [0000]    
       
                 
         
             
             
         
       
     
         [0068]    The present invention also relates to the compound of formula (7): 
         [0000]    
       
                 
         
             
             
         
       
     
         [0069]    The present invention also relates to the compound of formula (8) 
         [0000]    
       
                 
         
             
             
         
       
     
         [0070]    The present invention also relates to the compound of formula (9) 
         [0000]    
       
                 
         
             
             
         
       
     
         [0071]    The present invention also relates to the compound of formula (10) 
         [0000]    
       
                 
         
             
             
         
       
     
         [0072]    The present invention also relates to the compound of formula (11) 
         [0000]    
       
                 
         
             
             
         
       
     
         [0073]    The present invention also relates to processes for producing the compounds of formula (I), (II), and (III). 
         [0074]    The present invention also relates to a process for producing the compound of formula (1), comprising: 
         [0075]    a) mixing diglycidyl ester, methacrylic acid, 4-dimethoxyphenol (BHT), and a base, wherein the base is preferably 4-dimethylaminopyridine (DMAP), triethylamine, or triphenyl phosphine, 
         [0076]    b) adding phatallic anhydride dissolved in a polar solvent, wherein the solvent is preferably tetrahydrofuran. 
         [0077]    The present invention also relates to a process for producing the compound of formula (2), comprising: 
         [0078]    a) mixing diglycidyl ester, methacrylic acid, 4-dimethoxyphenol (BHT), and a base, wherein the base is preferably 4-dimethylaminopy dine (DMAP), triethylamine, triphenyl phosphine, or dimethylamino pyridine; 
         [0079]    b) adding succinic anhydride dissolved in a polar solvent, wherein the solvent is preferably tetrahydrofuran. 
         [0080]    The present invention also relates to a process for producing the compound of formula (3), comprising: 
         [0081]    a) mixing 3-(2-diethoxyphosphoryl)acetoxy)-2-hydroxypropyl methacrylate with diisocyanate, or mixing 3-(2-diethoxyphosphoryl)acetoxy)-2-hydroxypropyl methacrylate with a carboxylic acid and reacting with a dehydrating agent such as N,N′-dicyclohexylcarbodiimide (DCC); 
         [0082]    b) adding a catalyst preferably selected from the group consisting of: dibutyl tin dilaurate, KKAT A209 (a zirconium chelate complex dissolved in a reactive diluent and t-butyl acetate), zirconium acetylacetonate, and dioctyltin dilaurate (DOTDL); 
         [0083]    c) dissolving the resulting mixture in methylene chloride and trimethylsilylbromide; 
         [0084]    d) removing solvent; and 
         [0085]    e) adding methanol. 
         [0086]    The present invention also relates to a process for producing the compound of formula (4), comprising:
       a) mixing 3-(2-diethoxyphosphoryl)acetoxy)-2-hydroxypropyl methacrylate with Desmodur XP2410       
 
         [0000]    
       
                 
         
             
             
         
       
       
         
           
             b) adding a catalyst preferably selected from the group consisting of: dibutyl tin dilaurate, KKAT A209 (a zirconium chelate complex dissolved in a reactive diluent and t-butyl acetate), zirconium acetylacetonate, and dioctyltin dilaurate (DOTDL); 
             c) dissolving the resulting mixture in methylene chloride and methylsilylbromide; 
             d) removing solvent; and 
             e) adding methanol. 
           
         
       
     
         [0092]    The present invention also relates to a process for producing the compound of formula (5), comprising: 
         [0000]    a) mixing 3-(2-diethoxyphosphoryl)acetoxy)-2-hydroxypropyl methacrylate with 1,6-hexanediisocyanate,
 
b) adding a catalyst preferably selected from the group consisting of: dibutyl tin dilaurate, KKAT A209 (a zirconium chelate complex dissolved in a reactive diluent and t-butyl acetate; King Industries, Norwalk, Conn.), zirconium acetylacetonate, and dioctyltin dilaurate (DOTDL);
 
c) dissolving the resulting mixture in methylene chloride and trimethylsilylbromide;
 
d) removing solvent; and
 
e) adding methanol.
 
         [0093]    The present invention also relates to a process for producing the compound of formula (6), comprising: 
         [0000]    a) mixing 3-(2-diethoxyphosphoryl)acetoxy)-2-hydroxypropyl methacrylate with 2-isocyanoethyl methacrylate
 
b) adding a catalyst preferably selected from the group consisting of: dibutyl tin dilaurate, KKAT A209 (a zirconium chelate complex dissolved in a reactive diluent and t-butyl acetate; King Industries, Norwalk, Conn.), zirconium acetylacetonate, and dioctyltin dilaurate (DOTDL);
 
c) dissolving the resulting mixture in methylene chloride and trimethylsilylbromide;
 
d) removing solvent; and
 
e) adding methanol.
 
         [0094]    The present invention also relates to processes for producing the compound of formula (7), (8), (9), (10), and (11), comprising: protection of acid groups (ester formation), reaction of the alcohol with an acyl chloride (for example, methacryloyl chloride) in the presence of a base (for example, triethylamine), or reaction of the alcohol with an isocyanate (for example, isocyanatoethyl methacrylate) using a catalyst (for example Dibutyltin Dilaurate, or DBTDL), and cleavage of the protecting group. 
         [0095]    The present invention also relates to a composition comprising a compound of formula (I), formula (II), or formula (III), or a compound of formulas (1)-(11). In some embodiments, the composition further comprises one or more polymerizable methacrylic monomers selected from the group consisting of: 2,2-bis[4-2(hydroxyl-3-methacryloyloxypropyl)phenyl]propane (Bis-GMA), dimer dicarbamate dimethacrylate (DDCDMA), 1,6-bis-[2-methacryloyloxyethoxycarbonylamino]-2,4,4-trimethylhexane (UDMA), and 2,2-bis(4-(2-Methacryloxyethoxy)phenylpropane (Bis-EMA), and Poly (ethylene glycol) dimethacrylate (PEGDMA). 
         [0096]    In some embodiments, the composition further comprises hydrophilic methacrylate compounds selected from the group consisting of: 2-hydroxyethyl methacrylate (HEMA), triethylene glycol dimethacrylate (TEGDMA), ethylene glycoldimethacrylate (EGDMA), glycerol dimethcarylate (GDMA). 
         [0097]    In some embodiments, the composition further comprises a water soluble organic solvent selected from the group consisting of alcohol or ketones including but not limited to ethanol, propanol, acetone, and methylethyl ketone. 
         [0098]    In some embodiments, the compositions further comprise one or more filler materials or compounds. The composition may contain any filler material suitable for use in dental applications, including, but not limited to, silanized inorganic compounds. Filler materials include, but are not limited to, compounds which can increase viscosity and increase strength. In preferred embodiments, the compositions can comprise filler materials selected from the group consisting of: silanized inorganic compounds, silica, silicate glass, quartz, barium silicate, strontium silicate, barium borosilicate, strontium borosilicate, borosilicate, alumina, zirconia, tin oxide, ytterbium fluoride, and pigments. 
         [0099]    In some embodiments, the compositions can comprise pigments or coloring agents, inhibitors, and/or initiator systems. In some embodiments, the particle sizes of the one or more filler materials are between about 0.001 to about 5.0 micrometers. 
         [0100]    The present invention provides methods of using the compounds of formula (I), formula (II), or formula (III), or compounds (1)-(11) in dental applications. For example, the compounds may be used for dental applications including, but not limited to, dental adhesives; self adhesive restorative materials; permanent and temporary dental resin cements; light cure and chemical cure dental nanohybrid, microhybrid, and hybrid composites; dental nanohybrid and microhybrid flowable composites; temporary filling material; core build up material; and pit and fissure sealants. 
         [0101]    In some embodiments, the compounds can be used in dental adhesives in bonding dental biomaterials to hard tissues via a separate acid etching (total etch) or through a self-etching step without preparation of the hard tissue substrate. 
         [0102]    The compositions can be modified to affect properties such as pH, viscosity, rate of polymerization, final conversion, film thickness and bond strength. Thus, the adhesive compositions of the present invention may contain also contain in addition to the newly developed acid monomers: (a) one or more hydrophilic monomers in the amount of 5 to 90 wt %, preferably in the amount from 15 to 70 wt %, (b) one or more hydrophobic cross-linking compounds in the amount of 5 to 90 wt %, preferably in the amount from 20 to 70 wt %, (c) an organic water soluble solvent selected from the group of alcohols and ketones such as ethanol, propanol, acetone, methyl ethyl ketone; and (d) may or may not include water to hydrolyze the acid monomer and wet the hard tooth structure. 
         [0103]    In some embodiments, the adhesive composition can also be used with at least one initiator to allow photo and/or chemical curing. In some embodiments, the composition may additionally contain a co-initiator to accelerate the curing process. A photopolymerization inhibitor may also be included in the adhesive composition in order to increase shelf life and/or stability. 
         [0104]    The examples describe hereinafter are given for illustrative purpose only and are not intended to limit the scope of the invention. 
     
    
     
       DESCRIPTION OF THE FIGURES 
         [0105]      FIG. 1  shows the structure of 3-(2-(diethoxyphosphoryl)acetoxy)-2-hydroxypropyl methacrylate, which can be used as a starting material in the synthesis of compounds of the present invention. 
           [0106]      FIG. 2  shows the structures of commercial materials which can be used in the synthesis of compounds of the present invention. 
           [0107]      FIG. 3  shows the structure of polymerizable carboxylic acid compounds which can be used in compositions comprising the compounds of the present invention. 
           [0108]      FIG. 4  shows the structures of commercially available monomers used in dental adhesive formulations. 
           [0109]      FIG. 5  shows pH values of Part A self-etching adhesive compositions compared with commercial products, as described in Example 1. 
           [0110]      FIG. 6  shows water sorption and solubility for Part B, self-etching compositions, as described in Example 1. 
           [0111]      FIG. 7  shows double bond conversion values for Part B, self-etching compositions, as described in Example 1. 
           [0112]      FIG. 8  shows flexural strength and Young&#39;s modulus for Part B, self-etching compositions, as described in Example 1. 
       
    
    
     EXAMPLES 
     Example 1 
     Materials, Methods and Instruments 
       [0113]    The reactants and organic solvents utilized in the synthesis of the new monomers as well as known monomers and common resins were commercially obtained and were used as received. FT infrared spectra of thin films between KBr crystals were recorded on a Nicolet Nexus 670 spectrometer. The  1 H NMR and decouple  13 C NMR spectra were obtained on a Varian Inova 500-MHz spectrometer using CDCl 3  as the solvent. Monomers viscosities were measured on pure monomers at 25° C. with a parallel-plate viscometer (CAP 2000+; Brookfield Engineering Laboratories, Stoughton, Mass.). The test was run with spindles CAP-S-01 (900 rpm) or CAP-S-06 (200 rpm) depending on resin viscosity for 15 seconds. 
         [0114]    To permit photo-polymerization with visible light activation, 0.4 wt % camphorquinone and 0.8 wt % ethyl 4-N,N-dimethylaminobenzoate were mixed with the monomers, in some cases an acyl-phosphinoxide type photoinitiator was used. Dynamic and static photopolymerization studies were conducted with a visible light curing unit (Maxima Cure Power) on specimens prepared with a Delrin ring (inner dimensions: 1.25 mm thick and 12.5 mm diameter) sandwiched between glass cover slips irradiated for 40 s at 375 mW/cm 2 . Dynamic and static measurements of the methacrylate monomers conversion were accomplished with transmission near-infrared (NIR) spectroscopy (Nexus 670, Nicolet). The conversion values were determined from the change in the peak area of the methacrylate overtone absorption (═C—H at 6165 cm −1 ) before and after polymerization. Triplicate specimens of each monomer were polymerized and analyzed. Post-gel polymerization volumetric shrinkage was measured using an ACTA (Academic Center for Dentistry Amsterdam, Department of Materials Science, Amsterdam, The Netherlands) linometer. Polymer flexural strength and modulus were calculated using a three-point-bending test, carried out with a hydraulic universal test system (Instron, Norwood, Mass.). Water sorption and solubility were determinate according to ISO 4049. Shear bond strength test was carried out according to procedure described in Ultradent Products Inc.&#39;s U.S. Pat. No. 6,324,916 B1. The adhesive compositions of this invention comprise the so called one, two or three parts or bottles total etching, etch &amp; rinse, or self etching system. In example 10, one part or bottle adhesive compositions are described. Examples 11 to 14 refer to self etching adhesive compositions comprising two parts or two bottles. Generally, Part A comprises solvents, hydrophilic monomers, initiator, and inhibitor with or without filler. Example 15 refers to Part B bonding compositions which, in general, comprise hydrophilic or hydrophobic dimethacrylate, initiator, and inhibitor. Compositions may or may not contain fillers. 
       Example 2 
       [0115]    In a three neck flask, under nitrogen atmosphere were mixed 10.00 g (0.0145 mol) of dimer acid diglycidyl ester, 2.54 g (0.0290 mol) of methacrylic acid, 0.05 g of 4-dimethoxyphenol (BHT) and 0.20 g (0.0016 mol) of 4-dimethylaminopyridine (DMAP). The reaction mixture was heated at 90° C. for 24 hours. Mid-IR indicated complete reaction with the disappearance of epoxy ring at approximately 960 cm −1 . To continue, 4.3695 g (0.0290 mol) of phatallic anhydride dissolved in 30 mL of tetrahydrofurane (THF) were added drop wise. Once addition was finished the reaction mixture was refluxed for 6 days.  1 H NMR indicated 75% pure material. 
       Data for 1: 
       [0116]    IR (KBr, cm −1 ): ν 3052 (CH aromatic ), 2930, 2854 (CH aliphatic ), 1724, 1635 (CO), 1638 (═CH 2 ), 1600 (C═C) 
         [0117]      1 H NMR (500 MHz, CDCl 3 , ppm): δ 12.09 (s-br, COOH), 8.24, 8.20, 7.71, 7.67 (m, CH aromatic ), 6.15, 5.59 (m, ═CH 2 ), 5.15 (t, CH minority isomer ), 4.63-4.45 (m, OCH and OCH 2 ), 2.25 (m, CH 2 ), 1.98 (m, CH 3 ), 1.8-1.0 (m, CH and CH 2 ), 0.88 (m, CH 3 ). 
         [0118]      13 C{ 1 H} NMR (125 MHz, CDCl 3 , ppm): b 174.0, 169.3, 167.2, 165.9 (CO), 134.0, 133.0, 132.5, 130.0, 128.6 (CH aromatic ), 136.0 ( C H═CH 2 ), 126.2 (CH═ C H 2 ), 72.2, 68.0, 65.2, 62.9, 61.3 (OCH 2  and OCH), from 40 to 20 (CH and CH 2  aliphatic), 17.9 (CH 3 ), 14.1 (CH 3 ). 
         [0000]    
       
                 
         
             
             
         
       
     
       Example 3 
       [0119]    Under nitrogen atmosphere were mixed together 10.00 g (0.0145 mol) of dimer acid diglycidyl ester, 2.54 g (0.0290 mol) of methacrylic acid, 0.05 g of 4-dimethoxyphenol (BHT) and 0.20 g (0.0016 mol) of 4-dimethylaminopyridine (DMAP). The reaction mixture was heated at 90° C. for 24 hours. After allowing reaction mixture to reach room temperature, 2.95 g (0.0295 mol) of succinic anhydride dissolved in 30 mL of tetrahydrofurane (THF) were added drop wise. Once addition was finished the reaction mixture was refluxed for 4 days.  1 H NMR indicated 78% pure material. 
       Data for 2: 
       [0120]    IR (KBr, cm −1 ): ν 2945, 2852 (CH aliphatic ), 1722, 1635 (CO), 1638 (═CH 2 ). 
         [0121]      1 H NMR (500 MHz, CDCl 3 , ppm): δ 11.89 (s-br, COOH), 6.11, 5.58 (m, ═CH 2 ), 4.5-4.2 (m, OCH and OCH 2 ), 2.25 (m, CH 2 ), 1.98 (m, CH 3 ), 1.8-1.0 (m, CH and CH 2 ), 0.88 (m, CH 3 ). 
         [0122]      13 C{ 1 H} NMR (125 MHz, CDCl 3 , ppm): δ 177.3, 173.1, 167.2 (CO), 136.0 ( C H═CH 2 ), 125.2 (CH═ C H 2 ), 69.1, 64.5, 64.1 (OCH 2  and OCH), from 35 to 20 (CH and CH 2  aliphatic), 17.9 (CH 3 ), 14.1 (CH 3 ). 
         [0000]    
       
                 
         
             
             
         
       
     
       Example 4 
       [0123]    The synthesis of 3-(2-(diethoxyphosphoryl)acetoxy)-2-hydroxypropyl methacrylate ( FIG. 1 ) was carried out by the reaction of glycidyl methacrylate (20 g, 0.1407 mol) with diethylphosphonic acid) (28.97 g, 0.1477 mol) in the presence of a catalytic amount of triethylamine in absence of solvent.  1 H NMR was used to follow the reaction. The procedure had been described previously on “Journal of Polymer Science: Part A: Polymer Chemistry,” Vol. 46, No 6 (2008): pp. 2290-2299. 
         [0000]    
       
                 
         
             
             
         
       
     
         [0124]    Two alternative methods to synthesize the same compound were described by Youssef et al, “Macromol. Chem. Phys”. 2003, 204, 1842-1850. The first method consists of the reaction of the phosphonate epoxide and methacrylic acid in the presence of tetraethyl ammonium bromide using anhydrous toluene as solvent. The second one is a esterification between diethyl dihydroxy-1,2-propyl phosphate and methacryloyl chloride. 
       Example 5 
       [0125]    The synthesis of compound 5 required two steps. In Step 1: 6.94 g (0.0205 mol) of material described in Example 3 were mixed with 5.89 g (0.01 mol) of dimer acid diisocyanate and two drops of dibutyl tin dilaurate as the catalyst. Reaction mixture was stirred at 40° C. for 18 hours. Mid-IR showed completion of reaction indicated by disappearance of isocyanate peak at 2271 cm −1 . Step 2: the product obtained in step 2 was dissolved in 15 mL of methylene chloride (CH 2 Cl 2 ) and 2.51 g (0.0138 mol) of trimethylsilylbromide were added. Reaction mixture was reflux for 2 hours, solvent was removed with vacuum and then 20 mL of methanol were added. Reaction mixture was stirred at room temperature until next day. A slightly brown viscous liquid was obtained after evaporation of solvent. 4.26 g were obtained (yield: 93%). 
       Data for 3: 
       [0126]    IR (KBr, cm −1 ): ν 3349 (COOH), 2925, 2854 (CH aliphatic ), 2304 (PO—H), 1725 (CO), 1638 (═CH 2 ), 1257 (P═O). 
         [0000]    
       
                 
         
             
             
         
       
     
       Example 6 
       [0127]    The synthesis of compound 6 required three steps. Step 1: 5.2446 g (0.0155 mol) of material described in Example 3 were mixed with 2.5261 g (0.005 mol) of Desmodur XP2410 ( FIG. 2 ) and two drops of dibutyl tin dilaurate as the catalyst. Reaction mixture was stirred at 40° C. for 18 hours. Mid-IR showed completion of reaction indicated by disappearance of isocyanate peak at 2272 cm −1 . Step 2: 5.00 g (0.0033 mol) of product obtained in step 2 was dissolved in 15 mL of methylene chloride (CH 2 Cl 2 ) and 2.12 g (0.0138 mol) (4.2 equivalents) of trimethylsilylbromide were added. Reaction mixture was reflux for 2 hours, solvent was removed with vacuum and then 20 mL of methanol were added. Reaction mixture was stirred at room temperature until next day. A slightly yellow viscous liquid was obtained after evaporation of solvent. 
       Data for 4: 
       [0128]    IR (KBr, cm −1 ): ν 3360 (COOH), 2936, 2861 (CH aliphatic ), 2304 (PO—H), 1723, 1688 (CO), 1638 (═CH 2 ), 1247 (P═O). 
         [0000]    
       
                 
         
             
             
         
       
     
       Example 7 
       [0129]    The synthesis of compound 7 required two steps. Step 1: In a round bottom flask were mixed 3.18 g (0.0189 mol) of 1,6-hexanediisocyanate and 13.45 g (0.0976 mol) of product synthesized in Example 3. To continue three drops of dibutyl tin dilaurate were added. Reaction mixture was stirred at 40° C. for 18 hours. Mid-IR showed completion of reaction indicated by disappearance of isocyanate peak at 2270 cm −1 . Step 2: Product obtained above was dissolved in 25 mL of methylene chloride (CH 2 Cl 2 ) and 10.3 mL (4.2 equivalents) of trimethylsilylbromide were added. The resulting orange solution was reflux for 2 hours, and then solvent was evaporated. To continue, 20 mL of methanol were added and the solution was stirred at room temperature until next day. A yellow viscous liquid was obtained after evaporation of solvent. 
       Example 8 
       [0130]    The synthesis of compound 8 required two steps. Step 1: In a round bottom flask were mixed 15.52 g (0.1 mol) of 2-isocyantoethyl methacrylate and 34.19 g (0.101 mol) of product synthesized in Example 3 ( FIG. 1 ), to continue three drops of dibutyl tin dilaurate were added. Reaction mixture was stirred at 40° C. for 18 hours. Mid-IR showed completion of reaction indicated by disappearance of isocyanate peak at 2270 cm″Step 2: Product obtained above was dissolved in 50 mL of methylene chloride (CH 2 Cl 2 ) and 28.5 mL of trimethylsilylbromide were added. Reaction mixture was reflux for 2 hours, and then methylene chloride was removed with vacuum. To continue, 20 mL of methanol were added and the solution was stirred at room temperature until next day. A slightly yellow viscous liquid was obtained after evaporation of solvent. 
         [0000]    
       
                 
         
             
             
         
       
     
       Example 9 
       [0131]    The following chart shows example of pH of 37% solution of new synthesized monomers compared with commercial monomers used in dental adhesives 
         [0000]    
       
         
               
               
               
             
               
               
               
             
           
               
                   
               
               
                   
                 Mol. Wt 
                   
               
               
                 Monomer 
                 (g/mol) 
                 pH 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 1 
                 1145 
                 3.7 
               
               
                 2 
                 1049 
                 3.6 
               
               
                 PMGDMA 
                 675 
                 3.7 
               
               
                 4-META 
                 288 
                 1.2 
               
               
                   
               
               
                 PMGDMA and 4-META structures described on Figure 2 
               
             
          
         
       
     
       Example 10 
       [0132]    The following chart shows example of viscosity, degree of conversion and volume shrinkage obtained for some of the synthesized monomer 
         [0000]    
       
         
               
               
               
               
               
               
             
               
               
               
               
               
               
             
           
               
                   
                   
               
               
                   
                   
                   
                   
                   
                 Volume 
               
               
                   
                   
                 Mol. Wt 
                 Viscosity 
                 Conversion 
                 Shrinkage 
               
               
                   
                 Monomer 
                 (g/mol) 
                 (Pa*s) 
                 (%) 
                 (%) 
               
               
                   
                   
               
             
             
               
                   
               
             
          
           
               
                   
                 3 
                 1151 
                  1.65 ± 0.00 
                 75.2 ± 0.6 
                 2.6 ± 0.3 
               
               
                   
                 4 
                 1349 
                 15.5 ± 0.3 
                 81 ± 1 
                 2.8 ± 0.4 
               
               
                   
                 5 
                 732 
                 11.5 ± 0.1 
                 82 ± 1 
                 3.7 ± 0.2 
               
               
                   
                 6 
                 437 
                 11.9 ± 0.1 
                 71.2 ± 0.4 
                 5.8 ± 0.7 
               
               
                   
                   
               
             
          
         
       
     
       Example 11 
       [0133]    The following charts show example of one bottle self-etching compositions, with the amount of the components in wt % and pH obtained for each formulation 
         [0000]    
       
         
               
               
               
               
               
             
               
               
               
               
               
             
           
               
                   
               
               
                 Composition (%) 
                 Fl 
                 F2 
                 F3 
                 F4 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 HEMA 
                 25 
                 23 
                 22 
                 20 
               
               
                 (3) 
                 25 
                 25 
                 25 
                 25 
               
               
                 Bis-GMA 
                 40 
                 40 
                 40 
                 40 
               
               
                 Ethanol 
                 10 
                 10 
                 10 
                 10 
               
               
                 Water 
                 0 
                 2 
                 3 
                 5 
               
               
                 Total (%) 
                 100 
                 100 
                 100 
                 100 
               
               
                 pH 
                 a 
                 1.78 
                 1.60 
                 1.39 
               
               
                   
               
               
                   a  In anhydrous system pH cannot be determined 
               
             
          
         
       
     
         [0000]    
       
         
               
               
               
               
               
             
               
               
               
               
               
             
           
               
                   
               
               
                 Composition (%) 
                 G1 
                 G2 
                 G3 
                 G4 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 HEMA 
                 25 
                 23 
                 22 
                 20 
               
               
                 (4) 
                 25 
                 25 
                 25 
                 25 
               
               
                 Bis-GMA 
                 40 
                 40 
                 40 
                 40 
               
               
                 Ethanol 
                 10 
                 10 
                 10 
                 10 
               
               
                 Water 
                 0 
                 2 
                 3 
                 5 
               
               
                 Total (%) 
                 100 
                 100 
                 100 
                 100 
               
               
                 pH 
                 a 
                 0.49 
                 0.52 
                 0.51 
               
               
                   
               
               
                   a  In anhydrous system pH cannot be determined 
               
             
          
         
       
     
       Example 12 
       [0134]    The following chart shows example of Part A for two bottle self-etching compositions, with the amount of the components in wt % and camphorquinone/amine as the photoinitiator system. 
         [0000]    
       
         
               
               
               
               
             
           
               
                   
               
               
                   
                   
                 Monomer Ratio  
                 Ethanol/Water 
               
               
                 Formulation No. 
                 Monomers 
                 Wt % 
                 wt % 
               
               
                   
               
             
             
               
                 Part A (01) 
                 HEMA/(3)/BisGMA 
                 20/25/35 
                 18/2 
               
               
                 Part A (02) 
                 HEMA/(4)/BisGMA 
                 20/25/36 
                 18/2 
               
               
                 Part A (03) 
                 HEMA/(5)/BisGMA 
                 20/25/37 
                 17.5/2.5 
               
               
                 Part A (04) 
                 HEMA/(6)/BisGMA 
                 20/25/38 
                 18/2 
               
               
                 Part A (05) 
                 HEMA/(3)/BisGMA 
                 15/25/30 
                 28/2 
               
               
                 Part A (06) 
                 HEMA/(4)/BisGMA 
                 15/25/31 
                 28/2 
               
               
                 Part A (07) 
                 HEMA/(5)/BisGMA 
                 15/25/32 
                 27.5/2.5 
               
               
                 Part A (08) 
                 HEMA/(6)/BisGMA 
                 15/25/33 
                 28/2 
               
               
                   
               
               
                 Photoinitiator system: Camphorquinone 0.2 wt %/amine 0.8 wt % 
               
             
          
         
       
     
       Example 13 
       [0135]    The following chart shows example of Part A for two bottle self-etching compositions, with the amount of the components in wt % and Irgacure 1-819 as the photoinitiator system. 
         [0000]    
       
         
               
               
               
               
             
           
               
                   
               
               
                   
                   
                 Monomer Ratio 
                 Ethanol/Water 
               
               
                 Formulation No. 
                 Monomers 
                 Wt % 
                 wt % 
               
               
                   
               
             
             
               
                 Part A (09) 
                 HEMA/(3)/BisGMA 
                 20/25/35 
                 18/2 
               
               
                 Part A (10) 
                 HEMA/(4)/BisGMA 
                 20/25/36 
                 18/2 
               
               
                 Part A (11) 
                 HEMA/(5)/BisGMA 
                 20/25/37 
                 17.5/2.5 
               
               
                 Part A (12) 
                 HEMA/(6)/BisGMA 
                 20/25/38 
                 18/2 
               
               
                 Part A (13) 
                 HEMA/(3)/BisGMA 
                 15/25/30 
                 28/2 
               
               
                 Part A (14) 
                 HEMA/(4)/BisGMA 
                 15/25/31 
                 28/2 
               
               
                 Part A (15) 
                 HEMA/(5)/BisGMA 
                 15/25/32 
                 27.5/2.5 
               
               
                 Part A (16) 
                 HEMA/(6)/BisGMA 
                 15/25/33 
                 28/2 
               
               
                   
               
               
                 Photoinitiator system: Irgacure I-819 
               
             
          
         
       
     
       Example 14 
       [0136]    The following chart shows example of Part A formulation for two bottle self-etching compositions, with the amount of the components in wt % with conversion and viscosity values. 
         [0000]    
       
         
               
               
               
               
               
               
             
               
               
               
               
               
               
             
           
               
                   
               
               
                 Formulation 
                   
                 Monomer 
                 Ethanol/ 
                 Conversion 
                 Viscosity 
               
               
                 No. 
                 Monomers 
                 Ratio 
                 Water 
                 Day 0 
                 (mPa * s) 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 Part A (01) 
                 HEMA/(3)/ 
                 20/25/35 
                 18/2 
                 100 ± 0  
                 93.8 
               
               
                   
                 BisGMA 
                   
                   
                   
                   
               
               
                 Part A (02) 
                 HEMA/(4)/ 
                 20/25/36 
                 18/2 
                 98.0 ± 0.7  
                 72.2 
               
               
                   
                 BisGMA 
                   
                   
                   
                   
               
               
                 Part A (03) 
                 HEMA/(5)/ 
                 20/25/37 
                 17.5/2.5 
                 99.0 ± 0.1  
                 105.5 
               
               
                   
                 BisGMA 
                   
                   
                   
                   
               
               
                 Part A (04) 
                 HEMA/(6)/ 
                 20/25/38 
                 18/2 
                 99.0 ± 0.1  
                 60.3 
               
               
                   
                 BisGMA 
                   
                   
                   
                   
               
               
                 Part A (05) 
                 HEMA/(3)/ 
                 15/25/30 
                 28/2 
                   97 ± 0.39 
                 56 
               
               
                   
                 BisGMA 
                   
                   
                   
                   
               
               
                 Part A (06) 
                 HEMA/(4)/ 
                 15/25/31 
                 28/2 
                 97 ± 1 
                 38.5 
               
               
                   
                 BisGMA 
                   
                   
                   
                   
               
               
                 Part A (07) 
                 HEMA/(5)/ 
                 15/25/32 
                 27.5/2.5 
                 98 ± 1 
                 74.7 
               
               
                   
                 BisGMA 
                   
                   
                   
                   
               
               
                 Part A (08) 
                 HEMA/(6)/ 
                 15/25/33 
                 28/2 
                 98 ± 1 
                 30.5 
               
               
                   
                 BisGMA 
                   
                   
                   
                   
               
               
                 Part A (09) 
                 HEMA/(3)/ 
                 20/25/35 
                 18/2 
                  100 ± 0.06 
                 83 
               
               
                   
                 BisGMA 
                   
                   
                   
                   
               
               
                 Part A (10) 
                 HEMA/(4)/ 
                 20/25/36 
                 18/2 
                  100 ± 0.06 
                 110 
               
               
                   
                 BisGMA 
                   
                   
                   
                   
               
               
                 Part A (11) 
                 HEMA/(5)/ 
                 20/25/37 
                 17.5/2.5 
                 98.0 ± 0.6  
                 66.5 
               
               
                   
                 BisGMA 
                   
                   
                   
                   
               
               
                 Part A (12) 
                 HEMA/(6)/ 
                 20/25/38 
                 18/2 
                 100.0 ± 0.2  
                 70.7 
               
               
                   
                 BisGMA 
                   
                   
                   
                   
               
               
                 Part A (13) 
                 HEMA/(3)/ 
                 15/25/30 
                 28/2 
                  100 ± 0.17 
                 30 
               
               
                   
                 BisGMA 
                   
                   
                   
                   
               
               
                 Part A (14) 
                 HEMA/(4)/ 
                 15/25/31 
                 28/2 
                  100 ± 0.02 
                 90.5 
               
               
                   
                 BisGMA 
                   
                   
                   
                   
               
               
                 Part A (15) 
                 HEMA/(5)/ 
                 15/25/32 
                 27.5/2.5 
                 100 ± 0  
                 34 
               
               
                   
                 BisGMA 
                   
                   
                   
                   
               
               
                 Part A (16) 
                 HEMA/(6)/ 
                 15/25/33 
                 28/2 
                 100 ± 0  
                 69.8 
               
               
                   
                 BisGMA 
               
               
                   
               
             
          
         
       
     
       Example 15 
       [0137]    The following chart shows example of Part A compositions shelf life studies at 5° C. Conversion of compositions was evaluated as function of time. 
         [0000]    
       
         
               
               
               
               
               
               
               
             
           
               
                   
               
               
                 Formulation 
                 Day 0 
                 Day 15 
                 Day 30 
                 Day 45 
                 Day 60 
                 Day 90 
               
               
                 No. 
                 Conversion 
                 Conversion 
                 Conversion 
                 Conversion 
                 Conversion 
                 Conversion 
               
               
                   
               
             
             
               
                 Part A (01) 
                 100 ± 0  
                  100 ± 0.4  
                  97 ± 0.4 
                   98 ± 0.98 
                   99 ± 0.77 
                  100 ± 0.18 
               
               
                 Part A (02) 
                 98.0 ± 0.7  
                 99.0 ± .01  
                   98 ± 0.56 
                   96 ± 1.67 
                 96 ± 2  
                   97 ± 0.77 
               
               
                 Part A (03) 
                 99.0 ± 0.1  
                 99.0 ± 0.3  
                   99 ± 0.88 
                   99 ± 0.57 
                 96 ± 2  
                   98 ± 0.70 
               
               
                 Part A (04) 
                 99.0 ± 0.1  
                 99.00 ± 0.02  
                   99 ± 0.59 
                   99 ± 0.04 
                  97 ± 0.6 
                   99 ± 0.38 
               
               
                 Part A (05) 
                  97 ± 0.4 
                  100 ± 0.4  
                 73 ± 3  
                   96 ± 0.48 
                   98 ± 2.28 
                  100 ± 0.45 
               
               
                 Part A (06) 
                 97 ± 1  
                 91 ± 3  
                   97 ± 0.37 
                   97 ± 0.52 
                 92 ± 2  
                   97 ± 1.52 
               
               
                 Part A (07) 
                 98 ± 1  
                 95 ± 4  
                   93 ± 0.91 
                  95 ± 3.8 
                 94 ± 1  
                   95 ± 2.26 
               
               
                 Part A (08) 
                 98 ± 1  
                 98 ± 1  
                   98 ± 0.34 
                   99 ± 1.21 
                  97 ± 0.2 
                   99 ± 1.21 
               
               
                 WITH I-819 
                   
                   
                   
                   
                   
                   
               
               
                 Part A (09) 
                  100 ± 0.06 
                  100 ± 0.57 
                 100 ± 0  
                  100 ± 0.02 
                  100 ± 0.06 
                  100 ± 0.07 
               
               
                 Part A (10) 
                  100 ± 0.06 
                  100 ± .015 
                 100 ± 0  
                  100 ± 0.08 
                  100 ± 0.06 
                  100 ± 0.01 
               
               
                 Part A (11) 
                 98.0 ± 0.6  
                 100 ± 0  
                  100 ± 0.06 
                  100 ± 0.03 
                  100 ± 0.34 
                  100 ± 0.01 
               
               
                 Part A (12) 
                 100.0 ± 0.2  
                 100 ± 0  
                  100 ± 0.21 
                  100 ± 0.01 
                  100 ± 0.2  
                  100 ± 0.04 
               
               
                 Part A (13) 
                  100 ± 0.17 
                   99 ± 0.73 
                 100 ± 0  
                  100 ± 0.03 
                   99 ± 0.41 
                  100 ± 0.13 
               
               
                 Part A (14) 
                  100 ± 0.02 
                  100 ± 0.05 
                 99 ± 0  
                  100 ± 0.05 
                   99 ± 0.33 
                   
               
               
                 Part A (15) 
                 100 ± 0  
                  100 ± 0.35 
                  100 ± 0.19 
                  100 ± 0.03 
                   99 ± 0.45 
                  100 ± 0.02 
               
               
                 Part A (16) 
                 100 ± 0  
                  100 ± 0.14 
                   99 ± 1.10 
                  100 ± 0.21 
                   99 ± 0.58 
                  100 ± 0.06 
               
               
                   
               
             
          
         
       
     
       Example 16 
       [0138]    The following chart shows example of Part B formulations for two bottle self-etching compositions, with the amount of the components in wt % and camphorquinone/amine as the photoinitiator system. 
         [0000]    
       
         
               
               
               
             
           
               
                   
               
               
                   
                   
                 Monomer Ratio 
               
               
                 Formulation No. 
                 Monomers 
                 Wt % 
               
               
                   
               
             
             
               
                 Part B (01) 
                 BisGMA/TEGDMA 
                 70/30 
               
               
                 Part B (02) 
                 BisGMA/HEMA 
                 70/30 
               
               
                 Part B (03) 
                 BisEMA/DDCDMA 
                 70/30 
               
               
                 Part B (04) 
                 BisEMA/DDCDMA/UDMA 
                 60/25/15 
               
               
                 Part B (05) 
                 BisEMA/DDCDMA/(6)/UDMA 
                 60/12.5/12.5/15 
               
               
                 Part B (06) 
                 BisEMA/DDCDMA/(5)/UDMA 
                 60/12.5/12.5/15 
               
               
                 Part B (07) 
                 BisEMA/DDCDMA/(3)/UDMA 
                 60/12.5/12.5/15 
               
               
                 Part B (08) 
                 BisEMA/DDCDMA/(4)/UDMA 
                 60/12.5/12.5/15 
               
               
                   
               
             
          
         
       
     
       Example 17 
       [0139]    Shear bond strength (SBS) for two bottle self-etching experimental formulations and commercial products after 24 h at 37° C. 
         [0000]    
       
         
               
               
               
               
               
               
             
               
               
               
               
               
               
             
           
               
                   
               
               
                   
                   
                 Bond Strength 
                   
                   
                   
               
               
                   
                   
                 (Mpa)/Dry 
                   
                   
                   
               
               
                 Part A 
                 Part B 
                 Enamel 
                 WetEnamel 
                 DryDentin 
                 WetDentin 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 1 
                 2 
                 7.1 ± 2.1 
                   
                   
                   
               
               
                 2 
                 2 
                 8.6 ± 1.9 
                 8.9 ± 4.23 
                 8.6 ± 3.91 
                 14.5 ± 5.98 
               
               
                 3 
                 2 
                 6.2 ± 1.7 
                   
                   
                   
               
               
                 4 
                 2 
                 6.4 ± 2.1 
                   
                   
                   
               
               
                 5 
                 2 
                 7.5 ± 2.7 
                   
                   
                   
               
               
                 6 
                 2 
                 5.2 ± 1.0 
                   
                   
                   
               
               
                 7 
                 2 
                 3.6 ± 1.6 
                   
                   
                   
               
               
                 8 
                 2 
                 4.8 ± 1.9 
                   
                   
                   
               
               
                 1 
                 4 
                 8.1 ± 6.2 
                   
                   
                   
               
               
                 2 
                 4 
                 7.3 ± 1.8 
                   
                   
                   
               
               
                 3 
                 4 
                 6.9 ± 1.3 
               
               
                   
               
             
          
         
       
     
         [0000]    
       
         
               
               
               
             
           
               
                   
                   
               
               
                   
                 Commercial Products 
                 Bond Strength (MPa)/DryEnamel 
               
               
                   
                   
               
             
             
               
                   
                 Clearfil SE 
                 22.3 ± 3.15 
               
               
                   
                 Pro-Options 
                 13.4 ± 2.47 
               
               
                   
                 Confi-Quick 
                  9.9 ± 5.97 
               
               
                   
                 Adper Prompt 
                  8.5 ± 1.24 
               
               
                   
                 AdheSE 
                  9.3 ± 2.38 
               
               
                   
                 Optibond FL 
                 19.6 ± 3.45 
               
               
                   
                 Adper Scotchbond SE 
                 12.6 ± 1.31 
               
               
                   
                 DC Etchbond S2 
                  8.8 ± 1.95 
               
               
                   
                 Ace All-bond SE 
                  9.5 ± 1.54 
               
               
                   
                   
               
             
          
         
       
     
       Example 18 
       [0140]    The present invention relates to process of producing the compound of formula (7), (8), (9), (10), and (11), comprising: protection of acid groups (ester formation), reaction of the alcohol with an acyl chloride (for example, methacryloyl chloride) in the presence of a base (for example, triethylamine), or reaction of the alcohol with an isocyanate (for example, isocyanatoethyl methacrylate) using a catalyst (for example Dibutyltin Dilaurate, or DBTDL), and cleavage of the protecting group.